<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896777</url>
  </required_header>
  <id_info>
    <org_study_id>pH Study</org_study_id>
    <nct_id>NCT02896777</nct_id>
  </id_info>
  <brief_title>Triple-arm pH Comparison</brief_title>
  <acronym>Tri-pH</acronym>
  <official_title>Triple-arm Trial of pH (Tri-pH) Effect on Live Birth After ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ibn Sina Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Egyptian IVF Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banon IVF Center Assiut, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ibn Sina Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The culturing human embryo in vitro is a process of myriad contributing elements. From these
      factors is the pH of embryo culture media, which is crucial for embryo development. The
      investigators plan to examine three different pH values of the culture media on the live
      birth rate of in vitro cultured human embryos.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro fertilisation laboratory is the black box in which early human embryo development of
      infertile couple occurs. This laboratory holds many variables such as incubator type, air
      quality, brands of culture media, culture temperature and the pH of culture medium. Despite
      the importance of the culture medium pH, there is no single RCT has examined its effect on
      live birth rate post in vitro fertilisation. The investigators of this study believe that
      leaving this crucial element to the wishes of large companies and media designers is unwise.
      This RCT aims to provide a conclusive answer on pH effect on live birth rate of in vitro
      cultured human embryos.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 13, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live-birth rate</measure>
    <time_frame>&gt; 20 weeks of gestation</time_frame>
    <description>delivery of one or more viable infants &gt; 20 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>within 7 weeks of gestation</time_frame>
    <description>registered positive hCG ≥14 days after egg collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>≥ 7 weeks of gestation</time_frame>
    <description>presence of a foetal sac with a foetal heart beat on ultrasound &gt; 7 weeks of presence of a foetal sac with a foetal heart beat on ultrasound &gt; 7 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>within 24 weeks of pregnancy</time_frame>
    <description>Continued pregnancy after 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>within 42 weeks of pregnancy</time_frame>
    <description>Loss of pregnancy before week 20 of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Term Live birth rate</measure>
    <time_frame>≥ 37 weeks of gestation</time_frame>
    <description>Delivery of one or more viable infants ≥ 37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth-implantation rate</measure>
    <time_frame>within 42 weeks of gestation</time_frame>
    <description>Number of viable neonates per number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative live birth after one fresh and one frozen transfer</measure>
    <time_frame>within one year from randomization</time_frame>
    <description>Registered live birth from one fresh and one frozen cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth rate</measure>
    <time_frame>&lt;37 weeks of gestation</time_frame>
    <description>Delivery of one or more viable infants &lt;37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very preterm birth rate</measure>
    <time_frame>&lt;32 weeks of gestation</time_frame>
    <description>Delivery of one or more viable infants &lt;32 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Still birth</measure>
    <time_frame>42 weeks after ICSI</time_frame>
    <description>delivery of nonviable babies &gt; 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight babies</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>Viable neonate &lt; 2500 gm within 24 hours of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital malformation</measure>
    <time_frame>within 42 weeks of gestation</time_frame>
    <description>delivery of congenitally malformed babies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilisation rate</measure>
    <time_frame>Within 18 hours of inseminating the oocyte</time_frame>
    <description>Presence of 2 pronuclei17±1 hr post insemination/ICSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleavage rate</measure>
    <time_frame>Within 72 hours of inseminating the oocytes</time_frame>
    <description>registered divided embryo per fertilised oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High quality embryo on day 3</measure>
    <time_frame>Within 72 hours of inseminating the oocytes</time_frame>
    <description>embryo of 7 or more appropriate-size blastomeres with &lt; 10 fragmentation by volume per Istanbul Consensus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst formation rate on day 5/6</measure>
    <time_frame>Within 5-7 days of inseminating the oocytes</time_frame>
    <description>Formed blastocyst of any grade on day 5 or 6 per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-quality blastocyst rate on day 5</measure>
    <time_frame>5 Days of inseminating the oocytes</time_frame>
    <description>Blastocyst of ≥ 3.1.1.grading per Istanbul Consensus on day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryopreservation rate on day 5/6</measure>
    <time_frame>5-7 Days of inseminating the oocytes</time_frame>
    <description>Number of cryopreserved blastocyst on day 5 and 6 per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo utilization rate</measure>
    <time_frame>5-7 days post ICSI</time_frame>
    <description>Embryo Utilization rate (number of cryopreserved embryos added to the transferred embryos per fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top-quality embryo utilization rate</measure>
    <time_frame>5-7 days post ICSI</time_frame>
    <description>number of cryopreserved embryos added to the transferred embryos per fertilized oocytes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>In Vitro Fertilisation Outcome</condition>
  <arm_group>
    <arm_group_label>Transfer embryos from 7.20±0.02 pH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transfer embryos from 7.3±0.02 pH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transfer embryo from 7.4±0.02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6</intervention_name>
    <description>Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.</description>
    <arm_group_label>Transfer embryos from 7.20±0.02 pH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6</intervention_name>
    <description>Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.</description>
    <arm_group_label>Transfer embryos from 7.3±0.02 pH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6</intervention_name>
    <description>Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6</description>
    <arm_group_label>Transfer embryo from 7.4±0.02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age of ≥ 18 to ≤ 40

          2. BMI of ≤ 31

          3. Normal responder (≥ 10 antral follicle count (AFC) during basal ultrasound
             examination)

          4. PCOS

          5. Women who have ≥ 1 year of primary or secondary infertility

          6. Tubal factor (unilateral, bilateral obstruction or salpingectomy)

          7. Normal semen parameters

          8. Male factor: oligoasthenozoospermia or obstructive azoospermia

          9. Women who are undergoing their first IVF or ICSI cycle or second IVF Cycle with
             previous successful attempt

         10. Women who will undergo only fresh embryo transfer

         11. Women who have normal endometrial thickness (8-12) and echo-pattern at the time of hCG
             trigger

         12. Women who have normal transvaginal ultrasound during the follicular phase (defined as
             no intra cavity pathology; e.g. submucousal myomas, polyps or septa)

        Exclusion Criteria:

          1. Women who had unilateral oophorectomy

          2. Women who had uterine pathology or abnormality

          3. Women or their husbands who had abnormal karyotyping

          4. Women with history of recurrent abortions or repeated implantation failures

          5. Women who had uncontrolled diabetes

          6. Women with diagnosed or undiagnosed liver or renal disease

          7. Women who had a history of severe ovarian hyperstimulation

          8. Women who had history of malignancy or borderline pathology

          9. Women who will not meet the inclusion criteria

         10. Women who will refuse to participate in the study

         11. Women with endometriosis

         12. Patient undergoing PGS or PGD

         13. Severe male factor and non-obstructive azoospermia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Fawzy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ibnsina Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Fawzy, IVF Lab Director</last_name>
    <phone>+201011122286</phone>
    <email>drfawzy001@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banon Assiut</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banon Assiut</last_name>
    </contact>
    <investigator>
      <last_name>Mai Emad, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Egyptian IVF-ET Center</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ragaa Mansour, MD,PhD</last_name>
      <email>ragaa.mansour@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ragaa Mansour, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qena Fertility Center</name>
      <address>
        <city>Qena</city>
        <zip>123456</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abobkr Shabib, MD</last_name>
      <phone>+201011122286</phone>
      <email>drfawzy001@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amshaj</name>
      <address>
        <city>Sohag</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Fawzy, Lab Director</last_name>
      <phone>+201011122286</phone>
      <email>drfawzy001@me.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Elsuity, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IbnSina IVF Center</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Fawzy, IVF Lab Director</last_name>
      <phone>+201011122286</phone>
      <email>drfawzy001@me.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ibn Sina Hospital</investigator_affiliation>
    <investigator_full_name>Muhammad Fawzy</investigator_full_name>
    <investigator_title>IVF Lab Director</investigator_title>
  </responsible_party>
  <keyword>pH</keyword>
  <keyword>IVF</keyword>
  <keyword>live birth rate</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

